Moreover, cotreatment with anti-CD64 (FcγRI) antibody and PAD2 inhibitor rather than anti-CD32a (FcγRIIA) antibody and PAD4 inhibitor curbed ACPA-induced RA-FLS activation and osteoclastogenesis in RA patients (46). This evidence concerns the gene PADI4 and rheumatoid arthritis.